Dabigatran Etexilate Teva: Uses, Dosage & Side Effects
Direct oral anticoagulant (DOAC) – direct thrombin inhibitor (DTI) for stroke prevention and blood clot treatment
Quick facts about Dabigatran Etexilate Teva
Key Takeaways
- Dabigatran etexilate is a direct oral anticoagulant (DOAC) that prevents blood clots by directly and reversibly inhibiting thrombin (factor IIa), the central enzyme in the coagulation cascade.
- The RE-LY trial demonstrated that dabigatran 150 mg twice daily was superior to warfarin for stroke prevention in atrial fibrillation, while the 110 mg dose had significantly lower bleeding rates.
- Dabigatran is the only DOAC with a specific monoclonal antibody reversal agent – idarucizumab (Praxbind) – which immediately and completely reverses its anticoagulant effect.
- Kidney function must be assessed before starting dabigatran and monitored regularly during treatment, as approximately 80% is eliminated unchanged through the kidneys.
- Capsules must be swallowed whole and never opened or crushed, as removing the capsule shell increases bioavailability by approximately 75%, significantly raising bleeding risk.
What Is Dabigatran Etexilate Teva and What Is It Used For?
Quick Answer: Dabigatran etexilate Teva is a generic direct oral anticoagulant (DOAC) that belongs to the class of direct thrombin inhibitors (DTIs). It is used to prevent stroke in atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and prevent blood clots after hip or knee replacement surgery. It is bioequivalent to the original brand Pradaxa.
Dabigatran etexilate is a prescription anticoagulant medication that works through a unique mechanism among the direct oral anticoagulants. Unlike the factor Xa inhibitors (apixaban, rivaroxaban, edoxaban), dabigatran directly and reversibly inhibits thrombin (factor IIa), the central serine protease in the coagulation cascade. Thrombin plays a pivotal role in clot formation by converting fibrinogen to fibrin, activating factors V, VIII, XI, and XIII, and stimulating platelet aggregation. By blocking thrombin, dabigatran provides comprehensive anticoagulation at a key point in the clotting process.
Dabigatran etexilate itself is a prodrug with low intrinsic pharmacological activity. After oral administration, it is rapidly absorbed from the gastrointestinal tract and converted to the active form, dabigatran, by ubiquitous esterase-catalysed hydrolysis in the gut, plasma, and liver. This biotransformation is independent of cytochrome P450 enzymes, which gives dabigatran a distinctive drug interaction profile compared to factor Xa inhibitors.
The original dabigatran etexilate was developed by Boehringer Ingelheim and marketed under the brand name Pradaxa. It was the first direct oral anticoagulant approved by the European Medicines Agency (EMA) in 2008 and the U.S. Food and Drug Administration (FDA) in 2010. Dabigatran etexilate Teva is a generic version manufactured by Teva Pharmaceutical Industries, approved by the EMA as bioequivalent to Pradaxa. This means it has been demonstrated to produce the same blood levels and clinical effect as the original brand.
Dabigatran etexilate belongs to the broader family of direct oral anticoagulants (DOACs), sometimes called novel oral anticoagulants (NOACs). It is the only member of this class that targets thrombin directly, while the others (apixaban, rivaroxaban, edoxaban) target factor Xa. This distinction has practical implications, including dabigatran's unique susceptibility to reversal by idarucizumab, its primarily renal elimination, and its sensitivity to P-glycoprotein (P-gp) transport rather than CYP-mediated metabolism.
Approved Indications
Dabigatran etexilate Teva is approved for the following clinical indications, mirroring those of the originator product Pradaxa:
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) who have one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75, heart failure (NYHA class ≥II), diabetes mellitus, or hypertension.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults, following treatment with a parenteral anticoagulant administered for at least 5 days.
- Prevention of recurrent DVT and PE in adults who have completed initial treatment.
- Prevention of venous thromboembolism (VTE) in adult patients who have undergone elective hip or knee replacement surgery (primary prevention).
The European Society of Cardiology (ESC) 2024 guidelines recommend DOACs, including dabigatran, as the preferred oral anticoagulants over vitamin K antagonists (warfarin) for stroke prevention in patients with atrial fibrillation, except in patients with mechanical heart valves or moderate-to-severe mitral stenosis. Dabigatran is specifically noted for its advantage of having a licensed specific reversal agent.
Mechanism of Action
Dabigatran is a potent, competitive, reversible direct inhibitor of thrombin (factor IIa). Unlike heparin, which requires antithrombin III as a cofactor, dabigatran binds directly to the active site of thrombin and blocks its enzymatic activity. It inhibits free thrombin, fibrin-bound thrombin, and thrombin-induced platelet aggregation. By inhibiting thrombin, dabigatran prevents the conversion of fibrinogen to fibrin (the structural component of blood clots), the activation of coagulation factors V, VIII, XI, and XIII, and thrombin-mediated platelet activation. The result is effective prevention of new clot formation without directly dissolving existing clots.
The competitive and reversible nature of dabigatran's binding to thrombin means that its anticoagulant effect is closely related to plasma drug concentrations. As drug levels decline through elimination (primarily renal), the anticoagulant effect wears off predictably. This pharmacokinetic-pharmacodynamic relationship underpins the fixed-dose regimen used clinically and the effectiveness of idarucizumab as a reversal agent.
What Should You Know Before Taking Dabigatran Etexilate Teva?
Quick Answer: Before starting dabigatran, your doctor will assess your kidney function, bleeding risk, body weight, age, and other medications. Dabigatran is contraindicated in severe renal impairment (CrCl <30 mL/min), active clinically significant bleeding, prosthetic heart valves, and severe liver disease. Kidney function monitoring is essential both before and during treatment.
Before prescribing dabigatran etexilate Teva, your healthcare provider will conduct a comprehensive assessment of your medical history, current medications, kidney function, and overall health status. Because dabigatran is predominantly eliminated by the kidneys (approximately 80% as unchanged drug), renal function is a particularly critical factor in determining both eligibility for treatment and the appropriate dose. This contrasts with factor Xa inhibitors, which have more balanced hepatic and renal elimination pathways.
Contraindications
Dabigatran etexilate Teva should not be used in the following situations:
- Severe renal impairment: Patients with creatinine clearance (CrCl) below 30 mL/min are contraindicated for most indications, as the dramatically prolonged half-life leads to excessive drug accumulation and unacceptable bleeding risk. In the United States, the FDA permits use with caution down to CrCl 15 mL/min with a reduced dose of 75 mg twice daily for atrial fibrillation, but this dose is not available in all countries.
- Active clinically significant bleeding: Patients with ongoing haemorrhage from any site, including gastrointestinal, intracranial, or urogenital bleeding.
- Hypersensitivity: Known allergy to dabigatran etexilate, dabigatran, or any of the excipients in the formulation.
- Severe hepatic disease: Liver disease associated with coagulopathy or any liver disease expected to have an impact on survival. Although dabigatran is not metabolised by the liver through CYP enzymes, hepatic impairment can affect the esterase-mediated conversion of the prodrug and may be associated with underlying coagulation disturbances.
- Prosthetic heart valves: The RE-ALIGN trial was terminated early due to excess thromboembolic and bleeding events in patients with mechanical heart valves receiving dabigatran. Warfarin remains the only recommended anticoagulant for this population.
- Concomitant treatment with systemic ketoconazole, ciclosporin, itraconazole, dronedarone, and the fixed-dose combination of glecaprevir/pibrentasvir (strong P-gp inhibitors that significantly increase dabigatran levels).
- Lesions or conditions at significant risk of major bleeding: Such as current or recent gastrointestinal ulceration, malignant neoplasms at high risk of bleeding, recent brain or spinal injury, or oesophageal varices.
Premature discontinuation of dabigatran without switching to an alternative anticoagulant increases the risk of thrombotic events, including stroke. If you need to stop dabigatran for surgery or other reasons, your doctor will provide specific guidance on when to stop and restart the medication. The timing depends on your kidney function and the type of procedure. Never stop taking dabigatran without consulting your prescriber.
Warnings and Precautions
Special caution is required when using dabigatran etexilate in the following situations:
- Renal impairment: Because approximately 80% of dabigatran is eliminated unchanged through the kidneys, impaired renal function leads to increased drug exposure and prolonged anticoagulant effect. Creatinine clearance must be calculated before starting treatment. In patients with CrCl 30–50 mL/min, a dose reduction to 110 mg twice daily is recommended for atrial fibrillation in Europe. Kidney function should be reassessed at least annually, or more frequently in patients over 75 years, those with known renal impairment, or in clinical situations where renal function may decline (dehydration, concurrent nephrotoxic drugs, acute illness).
- Increased bleeding risk: Conditions that increase bleeding risk include age ≥75, moderate renal impairment, concomitant use of antiplatelet agents, NSAIDs, or other anticoagulants, low body weight (<50 kg), and gastrointestinal conditions predisposing to bleeding. Dabigatran has a higher rate of gastrointestinal bleeding compared to warfarin, particularly with the 150 mg dose.
- Gastrointestinal effects: Dabigatran contains tartaric acid in the capsule pellets, which is necessary for absorption but can cause dyspepsia, gastritis, and gastrointestinal discomfort. Taking the capsules with food or a full glass of water may help reduce these symptoms.
- Spinal or epidural anaesthesia: Patients receiving neuraxial anaesthesia or undergoing spinal/epidural puncture are at risk of developing epidural or spinal haematoma. Dabigatran should be discontinued at least 24 hours (CrCl ≥80 mL/min) or at least 48 hours (CrCl 50–80 mL/min) before the procedure.
- Surgery and invasive procedures: Dabigatran must be temporarily discontinued before surgical or invasive procedures. The duration of discontinuation depends on kidney function and the bleeding risk of the procedure. For standard-risk procedures, stop dabigatran 24 hours before (CrCl ≥80) or up to 96 hours before (CrCl 30–50). For high-risk procedures, double these intervals. In emergency situations, idarucizumab can provide immediate reversal.
- Elderly patients: Patients aged 75–80 years should be treated with a reduced dose of 110 mg twice daily for atrial fibrillation in some regulatory jurisdictions. Patients over 80 years should receive 110 mg twice daily according to EMA-approved labelling. Renal function monitoring should be more frequent in elderly patients.
Pregnancy and Breastfeeding
There are limited clinical data on the use of dabigatran during pregnancy. Animal studies have shown reproductive toxicity, including decreased foetal body weight and viability at maternally toxic doses. As a precautionary measure, dabigatran etexilate should not be used during pregnancy unless clearly necessary and only if the potential benefit outweighs the potential risk to the foetus. Women of childbearing potential should use effective contraception during treatment.
There are no clinical data on the effect of dabigatran on fertility in humans. Animal studies at high doses showed decreased implantations and an increase in pre-implantation loss. No other effects on female fertility were observed. Male fertility was not affected in animal studies.
It is not known whether dabigatran is excreted in human breast milk. No clinical data are available on the use of dabigatran during breastfeeding. As a precaution, breastfeeding should be discontinued during treatment with dabigatran etexilate Teva.
Kidney function (creatinine clearance) must be assessed: before starting treatment, at least annually during treatment, when a decline in renal function is suspected (e.g. hypovolaemia, dehydration, concurrent use of nephrotoxic agents), and more frequently (every 3–6 months) in patients over 75 years or with CrCl 30–50 mL/min. The Cockcroft-Gault formula should be used to estimate creatinine clearance.
How Does Dabigatran Etexilate Teva Interact with Other Drugs?
Quick Answer: Dabigatran is a substrate for the P-glycoprotein (P-gp) transporter but is not metabolised by cytochrome P450 enzymes. Strong P-gp inhibitors (ketoconazole, dronedarone, ciclosporin) are contraindicated as they significantly increase dabigatran levels. Strong P-gp inducers (rifampicin) significantly decrease dabigatran levels and should be avoided. Concomitant use of anticoagulants, antiplatelet agents, and NSAIDs increases bleeding risk.
The drug interaction profile of dabigatran differs fundamentally from that of factor Xa inhibitors (apixaban, rivaroxaban, edoxaban). Because dabigatran is converted from its prodrug form by esterases rather than cytochrome P450 enzymes, it does not have the CYP3A4-mediated interactions that are clinically important for other DOACs. Instead, the key interaction pathway for dabigatran involves the P-glycoprotein (P-gp) efflux transporter in the intestinal wall, which determines how much of the prodrug is absorbed.
Dabigatran etexilate (the prodrug) is a substrate for P-gp, but the active metabolite dabigatran is not. This means that P-gp inhibitors and inducers affect absorption of the prodrug from the gut, but do not significantly affect elimination of the active drug once it is in the systemic circulation. The effect is primarily on peak plasma concentration (Cmax) and area under the curve (AUC) through modulation of intestinal absorption.
It is essential to inform your prescriber about all medications you are taking, including over-the-counter medicines, herbal supplements, and vitamins. Although dabigatran has fewer CYP-mediated interactions than warfarin, several P-gp-related interactions are clinically significant and may require dose adjustment, alternative therapy, or are absolutely contraindicated.
Major Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Ketoconazole (systemic) | Strong P-gp inhibitor; increases dabigatran AUC by 138% and Cmax by 135% | Contraindicated – do not use concomitantly |
| Dronedarone | Moderate P-gp inhibitor; increases dabigatran AUC by approximately 70% | Contraindicated – do not use concomitantly |
| Ciclosporin, itraconazole, tacrolimus | Strong P-gp inhibitors; expected to significantly increase dabigatran levels | Contraindicated (ciclosporin, itraconazole) or not recommended (tacrolimus) |
| Rifampicin | Strong P-gp inducer; decreases dabigatran AUC by approximately 66% | Avoid concomitant use; dabigatran efficacy is substantially reduced |
| Carbamazepine, phenytoin, St John’s Wort | P-gp inducers; expected to significantly decrease dabigatran levels | Avoid concomitant use |
| Other anticoagulants (heparin, warfarin, enoxaparin) | Additive anticoagulant effect; markedly increased bleeding risk | Avoid concomitant use except during transition between anticoagulants |
Minor Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Amiodarone | P-gp inhibitor; increases dabigatran AUC by 50–60% | Consider dose reduction to 110 mg twice daily in atrial fibrillation; use with caution |
| Verapamil | P-gp inhibitor; increases dabigatran Cmax and AUC by 12–180% depending on timing | Reduce dose to 110 mg twice daily; take dabigatran at least 2 hours before verapamil |
| Quinidine | P-gp inhibitor; increases dabigatran levels | Consider dose reduction; use with caution |
| NSAIDs (ibuprofen, naproxen, diclofenac) | Do not alter dabigatran levels but independently increase bleeding risk, particularly gastrointestinal | Use short courses only when clinically indicated; avoid long-term concomitant use |
| Aspirin, clopidogrel, ticagrelor | Antiplatelet agents; additive bleeding risk | Use only when clinically indicated; monitor for signs of bleeding |
| SSRIs/SNRIs (fluoxetine, venlafaxine) | May impair platelet function and increase bleeding risk | Use with caution; monitor for unusual bleeding |
| Proton pump inhibitors (omeprazole, pantoprazole) | Reduce dabigatran AUC by approximately 20–30% by raising gastric pH | No dose adjustment required; clinical significance considered minor |
Unlike warfarin, dabigatran does not interact with vitamin K-containing foods. You do not need to restrict your intake of green leafy vegetables or other vitamin K-rich foods. Dabigatran can be taken with or without food. However, taking it with food delays the time to peak concentration (Tmax) by approximately 2 hours without significantly affecting the overall extent of absorption (AUC). The tartaric acid core in the capsule pellets provides an acidic microenvironment necessary for absorption, which is why the capsules should not be opened or crushed.
What Is the Correct Dosage of Dabigatran Etexilate Teva?
Quick Answer: The standard dose of dabigatran varies by indication and patient characteristics. For atrial fibrillation, the recommended dose is 150 mg twice daily, with a reduced dose of 110 mg twice daily for patients aged ≥80 or those taking verapamil. For VTE prevention after surgery, the dose is 110 mg once on the day of surgery, followed by 220 mg once daily. The 75 mg capsule is used in specific situations.
Dabigatran dosing depends on the indication being treated, the patient's age, kidney function, body weight, and concomitant medications. Unlike warfarin, dabigatran uses fixed doses and does not require individualised titration based on coagulation tests. However, correct dose selection is essential, as the available strengths (75 mg, 110 mg, and 150 mg) serve different clinical purposes. Always take the dose prescribed by your doctor.
Adults
| Indication | Standard Dose | Reduced Dose | Duration |
|---|---|---|---|
| Stroke prevention in atrial fibrillation | 150 mg twice daily | 110 mg twice daily* | Long-term (indefinite) |
| Treatment of DVT/PE | 150 mg twice daily (after ≥5 days parenteral anticoagulation) | 110 mg twice daily* | At least 3–6 months |
| Prevention of recurrent DVT/PE | 150 mg twice daily | 110 mg twice daily* | Extended (based on individual risk-benefit assessment) |
| VTE prevention after hip replacement | 220 mg once daily (110 mg on day of surgery, then 220 mg daily) | 150 mg once daily** | 28–35 days |
| VTE prevention after knee replacement | 220 mg once daily (110 mg on day of surgery, then 220 mg daily) | 150 mg once daily** | 10 days |
*Reduced dose of 110 mg twice daily is recommended for patients aged ≥80 years, patients taking concomitant verapamil, patients at higher bleeding risk, and patients with CrCl 30–50 mL/min (in some jurisdictions). For patients aged 75–80, the 110 mg dose should be considered.
**Reduced dose of 150 mg once daily (75 mg on day of surgery, then 150 mg daily) for patients with moderate renal impairment (CrCl 30–50 mL/min), age ≥75, or taking concomitant moderate P-gp inhibitors.
The Role of the 75 mg Capsule
The 75 mg hard capsule serves specific clinical purposes. In the EMA-approved regimen, it is primarily used as the initial dose on the day of surgery for VTE prevention (half of the daily maintenance dose). In the United States, the FDA has approved a 75 mg twice daily dose for atrial fibrillation in patients with severe renal impairment (CrCl 15–30 mL/min). However, this dose is not available in all regulatory jurisdictions, and the clinical evidence for this dose is more limited.
Children
Dabigatran etexilate is not recommended for use in children and adolescents under 18 years of age. There are insufficient data on safety and efficacy in this population. For paediatric patients requiring anticoagulation, alternative agents such as heparin, low-molecular-weight heparin, or warfarin should be used under specialist paediatric haematology guidance.
Elderly
Age-related decline in renal function is common and directly affects dabigatran exposure. The following age-specific dose recommendations apply for atrial fibrillation:
- Age 75–80 years: 150 mg twice daily or 110 mg twice daily, based on individual assessment of thromboembolic risk versus bleeding risk. The EMA recommends considering 110 mg twice daily in this age group.
- Age ≥80 years: 110 mg twice daily (EMA recommendation). The lower dose is mandated due to the increased bleeding risk in very elderly patients.
- All elderly patients: Kidney function should be assessed more frequently (at least every 6 months for patients aged ≥75, and every 3 months in those with CrCl 30–50 mL/min).
Missed Dose
What to Do If You Miss a Dose
If you forget to take a dose of dabigatran, take it as soon as you remember, provided there are still at least 6 hours before the next scheduled dose. If fewer than 6 hours remain until the next dose, skip the missed dose entirely and take the next dose at the usual time. Do not take a double dose to make up for the missed one, as this significantly increases bleeding risk. If you frequently forget doses, consider using a reminder system such as a pill organiser or smartphone alarm.
Overdose
There is no general antidote for dabigatran overdose. However, idarucizumab (Praxbind) is a specific reversal agent that immediately and completely reverses the anticoagulant effect of dabigatran. In cases of overdose with life-threatening or uncontrolled bleeding, idarucizumab 5 g should be administered intravenously. Additional measures include maintenance of adequate diuresis (as dabigatran is primarily renally eliminated), surgical haemostasis, volume replacement, and consideration of activated prothrombin complex concentrates or recombinant factor VIIa if idarucizumab is unavailable. Dabigatran is dialysable (approximately 50–60% can be removed after 4 hours of haemodialysis), which provides an additional option in emergency situations.
What Are the Side Effects of Dabigatran Etexilate Teva?
Quick Answer: The most common side effects of dabigatran include gastrointestinal symptoms (dyspepsia, abdominal pain, nausea) and bleeding. Dabigatran has a higher rate of gastrointestinal bleeding compared to warfarin but a lower rate of intracranial bleeding. Dyspepsia occurs in approximately 11% of patients due to the tartaric acid content of the capsule pellets.
Like all anticoagulants, dabigatran increases the risk of bleeding. The type and severity of bleeding-related side effects have been extensively characterised in large clinical trials, including the RE-LY trial (over 18,000 patients), and in post-marketing surveillance. In addition to bleeding, dabigatran has some unique gastrointestinal side effects related to its formulation. The tartaric acid core in each capsule pellet creates an acidic microenvironment necessary for drug absorption but can irritate the gastrointestinal mucosa.
The following side effects are organised by frequency, in accordance with international convention (MedDRA frequency categories). It is important to note that not everyone will experience these side effects, and many people take dabigatran without any significant problems. If you experience any unusual symptoms, contact your healthcare provider.
Very Common (affects more than 1 in 10 people)
- Dyspepsia (indigestion, stomach discomfort, bloating)
- Minor bleeding (e.g. small bruises, nosebleeds, bleeding gums)
Common (affects 1 to 10 in every 100 people)
- Gastrointestinal bleeding (blood in stool, black or tarry stools)
- Abdominal pain
- Nausea
- Diarrhoea
- Gastritis (inflammation of the stomach lining)
- Gastro-oesophageal reflux disease (GORD)
- Urogenital bleeding (blood in urine)
- Skin bleeding (bruising, petechiae)
- Anaemia (reduction in red blood cells due to bleeding)
- Decreased haemoglobin levels
- Abnormal liver function tests (elevated ALT, AST)
Uncommon (affects 1 to 10 in every 1,000 people)
- Intracranial bleeding (bleeding within the skull)
- Rectal bleeding
- Haemorrhoidal bleeding
- Gastric or duodenal ulcer, including bleeding ulcers
- Oesophagitis
- Dysphagia (difficulty swallowing)
- Thrombocytopenia (reduced platelet count)
- Hypersensitivity reactions (rash, pruritus)
- Haemoptysis (coughing up blood)
- Wound bleeding or post-procedural haemorrhage
- Epistaxis (nosebleeds) requiring medical attention
Rare (affects 1 to 10 in every 10,000 people)
- Anaphylactic reactions (severe allergic reaction)
- Angioedema (swelling of face, lips, tongue, or throat)
- Urticaria (hives)
- Hepatic function abnormal / hepatocellular damage
- Bronchospasm
- Retroperitoneal bleeding
- Intra-articular bleeding (bleeding into joints)
- Intramuscular bleeding
- Alopecia (hair loss)
Contact your doctor or seek emergency medical care immediately if you experience: signs of severe bleeding (vomiting blood, black or bloody stools, unexplained severe bruising, blood in urine that is pink or red, prolonged bleeding from cuts, severe headache, dizziness, or weakness), signs of stroke (sudden numbness, confusion, vision changes, difficulty walking, severe headache), or signs of a severe allergic reaction (difficulty breathing, swelling of face/throat, severe rash).
Dyspepsia and gastrointestinal discomfort are more common with dabigatran than with other DOACs. This is because each dabigatran capsule contains tartaric acid-coated pellets. The tartaric acid creates an acidic microenvironment (pH approximately 2) that is essential for adequate absorption of the prodrug, but can irritate the gastric and oesophageal mucosa. Taking dabigatran with a full glass of water and with food may help reduce these symptoms. Proton pump inhibitors (PPIs) can be used to manage persistent dyspepsia, with only a minor (~20–30%) reduction in dabigatran absorption that is not considered clinically significant.
How Should You Store Dabigatran Etexilate Teva?
Quick Answer: Store dabigatran capsules in the original packaging (blister or bottle) to protect from moisture. Do not store above 30°C. Once opened, bottles must be used within 4 months. Do not put capsules in pill organisers or other containers, as exposure to moisture can reduce the drug's effectiveness.
Dabigatran etexilate capsules are sensitive to moisture, which can degrade the drug and reduce its effectiveness. Proper storage is therefore essential to maintain the quality and potency of the medication throughout its shelf life. The following storage guidelines should be strictly followed:
- Temperature: Store below 30°C (86°F). Do not refrigerate or freeze.
- Moisture protection: Keep the capsules in their original packaging at all times. For blister packs, do not remove a capsule from the blister until immediately before taking it. For bottles, keep the bottle tightly closed with the desiccant cap in place.
- Blister packs: Peel back the foil backing to remove the capsule. Do not push the capsule through the blister, as this can damage the capsule.
- Bottles: Once opened, the capsules must be used within 4 months. Note the date of opening on the bottle label.
- Pill organisers: Do not transfer dabigatran capsules to pill boxes or weekly organisers, as this exposes them to moisture and can significantly reduce their potency.
- Expiry date: Do not use the capsules after the expiry date stated on the packaging. Dispose of expired capsules according to local guidelines – do not flush down the toilet or throw in household waste.
- Keep out of reach of children: Store in a safe location where children cannot access the medication.
What Does Dabigatran Etexilate Teva Contain?
Quick Answer: Each capsule contains dabigatran etexilate (as mesilate) as the active ingredient, along with tartaric acid (essential for absorption), hypromellose, hydroxypropylcellulose, talc, and other excipients. The capsule shell is made of hypromellose and contains carrageenan, potassium chloride, titanium dioxide, and colourants.
Active Ingredient
The active ingredient is dabigatran etexilate, present as the mesilate salt. Dabigatran etexilate is a prodrug that is enzymatically converted to the pharmacologically active form, dabigatran, after oral ingestion. Each hard capsule contains 75 mg of dabigatran etexilate (equivalent to approximately 86.48 mg of dabigatran etexilate mesilate).
Excipients
The capsule contents and shell contain the following inactive ingredients:
- Tartaric acid: A critical excipient that creates an acidic microenvironment around the drug pellets, essential for the absorption of dabigatran etexilate. This is the component responsible for the gastrointestinal side effects seen with dabigatran.
- Hypromellose (HPMC): Used as a capsule shell material and as a coating agent for the drug pellets.
- Hydroxypropylcellulose: A binding and film-forming agent in the pellet formulation.
- Talc: Used as an anti-adherent and glidant.
- Dimethicone: Anti-foaming agent.
- Carrageenan: Used in the capsule shell as a gelling agent.
- Potassium chloride: Contributes to capsule shell formation.
- Titanium dioxide (E171): White colourant in the capsule shell.
- Iron oxide yellow (E172): Colourant in the capsule shell (strength-dependent).
- Sunset yellow FCF (E110): Colourant (may cause allergic reactions in susceptible individuals).
- Black printing ink: Contains shellac, propylene glycol, iron oxide black (E172), and potassium hydroxide for capsule imprinting.
Dabigatran etexilate Teva capsules contain sunset yellow FCF (E110), which may cause allergic reactions in some individuals. If you have a known sensitivity to azo dyes, inform your doctor before starting treatment. The capsule shells are made from hypromellose (HPMC) rather than gelatin, making them suitable for patients who need to avoid animal-derived gelatin for dietary, religious, or ethical reasons.
Frequently Asked Questions About Dabigatran Etexilate Teva
Dabigatran etexilate is a direct oral anticoagulant (DOAC) used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), to prevent recurrent DVT and PE, and to prevent venous thromboembolism (VTE) after elective hip or knee replacement surgery. It works by directly inhibiting thrombin (factor IIa), a key enzyme in the blood clotting cascade.
Dabigatran etexilate Teva is a generic version of Pradaxa (the original brand). Both contain the same active ingredient (dabigatran etexilate) and have been shown to be bioequivalent, meaning they produce the same blood levels and have the same clinical effect. The EMA has approved Dabigatran etexilate Teva as therapeutically equivalent to Pradaxa. The main difference may be in the inactive ingredients (excipients) and price, with generics typically being more affordable.
Unlike warfarin, dabigatran does not require routine coagulation monitoring such as INR tests. However, kidney function tests (creatinine clearance) are essential before starting dabigatran and should be checked at least annually during treatment, as approximately 80% of dabigatran is eliminated through the kidneys. More frequent monitoring (every 3–6 months) is recommended in patients over 75 years or those with reduced kidney function (CrCl 30–50 mL/min).
No. Dabigatran etexilate capsules must be swallowed whole with water. They should never be opened, crushed, or chewed. Removing the capsule shell increases bioavailability by approximately 75%, which significantly raises the risk of bleeding. The capsule shell is designed to protect the tartaric acid-coated pellets and control drug release. If you have difficulty swallowing capsules, speak with your doctor about alternative anticoagulant options, such as apixaban (which can be crushed) or rivaroxaban (which can be crushed for certain doses).
Yes. Idarucizumab (Praxbind) is a specific reversal agent approved for dabigatran. It is a humanised monoclonal antibody fragment that binds to dabigatran with very high affinity (approximately 350 times stronger than thrombin), immediately and completely reversing its anticoagulant effect within minutes. Idarucizumab is administered as a 5 g intravenous dose and is used in emergency situations such as life-threatening bleeding or urgent surgery. Dabigatran is the only DOAC with a specific monoclonal antibody reversal agent. Additionally, dabigatran is dialysable, providing a further option for removal in emergencies.
If you miss a dose, take it as soon as you remember, provided there are still at least 6 hours before the next scheduled dose. If fewer than 6 hours remain, skip the missed dose and take the next dose at the usual time. Do not take a double dose to make up for the missed one. Missing doses increases your risk of blood clots, so try to take dabigatran consistently at the same times each day. If you frequently forget doses, speak with your pharmacist about reminder strategies.
The landmark RE-LY trial (over 18,000 patients) demonstrated that dabigatran 150 mg twice daily was superior to warfarin for stroke prevention in atrial fibrillation, with a significant 35% relative risk reduction in stroke and systemic embolism. The 110 mg dose was non-inferior to warfarin with significantly lower rates of major bleeding. Both doses showed significantly lower rates of intracranial haemorrhage compared to warfarin. Unlike warfarin, dabigatran has fixed dosing, no routine INR monitoring, fewer food interactions, and a specific reversal agent (idarucizumab). However, warfarin remains preferred for mechanical heart valves, as the RE-ALIGN trial showed excess events with dabigatran in this population.
References and Sources
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation (RE-LY). New England Journal of Medicine. 2009;361(12):1139-1151. doi:10.1056/NEJMoa0905561
- European Society of Cardiology (ESC). ESC/EACTS Guidelines for the management of atrial fibrillation. European Heart Journal. 2024. doi:10.1093/eurheartj/ehae176
- European Medicines Agency (EMA). Summary of Product Characteristics – Pradaxa (dabigatran etexilate). Last updated 2024. EMA/EPAR/Pradaxa
- Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal – Full Cohort Analysis (RE-VERSE AD). New England Journal of Medicine. 2017;377(5):431-441. doi:10.1056/NEJMoa1707278
- Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER). New England Journal of Medicine. 2009;361(24):2342-2352. doi:10.1056/NEJMoa0906598
- Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement (RE-NOVATE). Lancet. 2007;370(9591):949-956. doi:10.1016/S0140-6736(07)61445-7
- American Heart Association / American College of Cardiology (AHA/ACC). AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation. 2023.
- British National Formulary (BNF). Dabigatran etexilate. Last reviewed 2025. BNF/Dabigatran
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd edition. 2023.
- Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves (RE-ALIGN). New England Journal of Medicine. 2013;369(13):1206-1214. doi:10.1056/NEJMoa1300615
Editorial Team
Written by
iMedic Medical Editorial Team
Specialists in Clinical Pharmacology, Haematology and Internal Medicine
Reviewed by
iMedic Medical Review Board
Independent panel of medical experts following GRADE evidence framework
Evidence Standards: All medical information is based on peer-reviewed clinical trials (including the landmark RE-LY, RE-COVER, and RE-NOVATE studies), international guidelines (ESC 2024, AHA/ACC 2023, WHO), regulatory documents (EMA SmPC, FDA label), and authoritative pharmacological references (BNF, Martindale). Evidence level: 1A – systematic reviews and meta-analyses of randomised controlled trials.
Last medically reviewed: | Meet our medical team | Editorial standards